
Here’s what patients should know about the recent FDA approval of Exkivity, the first oral therapy for patients with non-small cell lung cancer who have EFGR exon 20 insertion mutations.

Here’s what patients should know about the recent FDA approval of Exkivity, the first oral therapy for patients with non-small cell lung cancer who have EFGR exon 20 insertion mutations.

Geographic disparities at the state-level are leading to increased rates of death from lung cancer, according to an expert.

The first patient was treated in the phase 2b KICKSTART trial testing the safety and efficacy of tomivosertib in combination with Keytruda.

The prescription of systemic cancer therapies varies based on a patient’s age, comorbidities, cancer stage and other variables, according to recent research.

Ms. Addario, lung cancer survivor, encourages patients with non-small cell lung cancer to use all the resources and tools that are available to them.

Ms. Addario shares the promising hope for patients with lung cancer and describes the steps in the process of biomarker testing for patients with lung cancer.

Treating patients with lung cancer by identifying specific biomarkers to use the correct combination therapy and what it means for a biomarker to be actionable.

The average survival for patients with malignant pleural mesothelioma was less than a month after being diagnosed with COVID-19, according to a small study.

The eligible age of 65 years for Medicare may be discouraging patients from getting screenings and tests as they wait for more health coverage.

The FDA’s approval of Exkivity marks the first approved oral therapy for this subgroup of patients with non-small cell lung cancer.

Although immunotherapy has provided patients with small cell lung cancer with a “light at the end of the tunnel,” an expert from City of Hope argues more research is needed.

A retired New York City firefighter recalls his return to the city he once served for more than three decades on the day prior to the 9/11 terrorist attacks and all that followed, including his several bouts with lung cancer years after the dust had settled.

Retired FDNY firefighter and lung cancer survivor Jerry Sanford spoke about how he helped the rescue efforts following the Sept. 11 terrorist attacks in New York City.

The impact from 9/11 continues to this day, including the increased risk for cancer in first responders and survivors who inhaled the toxins contained in the air around ground zero.

Increased use of radiation in lung cancer treatment may be a result of discoveries in research and improved spreading of information on this technology.

Soon after the 9/11 terrorist attacks, Judy Meyers returned to work in Manhattan, despite the terrible air quality. Years later, she was diagnosed with lung cancer, which is directly related to being in New York City in the aftermath of the destruction of the Twin Towers.

More focus is needed on increasing lung cancer screening for patients, especially in those who are eligible for it according to their smoking history.

New advancements in the staging process for lung cancer are leading to faster recoveries and better diagnoses.

Clinical trials are an invaluable resource to the cancer community, as they continually advance treatment options for patients. An expert explains how they work and what patients should know.

Treating lung cancer is more precise than ever, thanks to biomarker testing, which gives clinicians a better understanding of individual’s tumors.

Surgery for malignant pleural mesothelioma after radiotherapy may increase overall survival rates, according to a study. However, study authors note that the procedure should only be adopted in centers with substantial surgical experience.

“I didn’t think that we were involved in great change, but then change became the name of the game.” — Loretta Ford

A colleague nominates Jody Ruth Steinhardt for the Lung Cancer Heroes® award for her commitment to changing the world for patients with lung cancer.

Patients with non-small cell lung cancer had rapid uptake of immunotherapy-containing regimens, but a shorter overall survival than patients in clinical trials.

A patient's husband writes about the persistence and passion of her oncologist, Dr. Bruno Fang, in helping her through treatment for stage 4 lung cancer.